University of Minnesota joins in academic partnership
Rune Labs, a software developer enabling the next wave of biofeedback in neuroscience therapeutics, announced a $5 million seed round led by DigiTx Partners. Other participating investors include TruVenturo, Moment Ventures, Loup Ventures and Sabbatical Ventures. Since the company’s founding in 2018, Rune Labs has raised a total of $7.3 million.
Rune Labs partners with leading medtech and pharmaceutical companies to label, organize, and analyze brain data. Rune Labs is focused on supporting neuromodulation therapies such as Deep Brain Stimulation (DBS) and Transcranial Magnetic Stimulation (TMS). Current device-based therapies generate a lot of data, including directly from brain signals. The mass of data is currently underutilized in trials and patient care as DBS and TMS manufacturers do not have a way to manage brain data at a large scale.
“Over the past two decades, we have witnessed tremendous improvements in neurostimulation devices for multiple neurologic conditions. What we are now seeing is the power of the information that could be derived from these devices. The technology Rune Labs is developing with neurologic and biometric data will optimize clinical care for many individuals with debilitating neurological and mental health conditions,” said David J. Kim, Managing Director, DigiTx Partners.
Using their platform, Rune Labs can sequence brain data both longitudinally for a single patient and across multiple patients, studies, and centers to be analyzed with machine learning tools. They are able to work with industry standard systems from Medtronic and Abbott as well as mobile health apps and devices… and they are and fully HIPAA compliant.
“This round of funding, following closely on last year’s, continues to validate our approach, technology and strategy,” said Brian Pepin, founder and CEO, Rune Labs. “Strong financial backing from credible partners and world-class academic collaborators continues to position us to help better understand the brain in order to improve neuromodulation therapies that can improve the quality of patients’ lives.”
The company will use the funds to continue to invest in R&D and to develop additional products.
About Rune Labs
Rune Labs, Inc. takes brain imaging and electrophysiology data generated in the course of clinical studies and patient care and makes this data useful for neuroscience therapeutics. We partner closely with med-tech and pharma companies to help develop and deliver precision therapies for Parkinson's disease, Epilepsy, Depression, Obsessive Compulsive Disorder, and other brain diseases. For more information visit www.runelabs.io.